Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2026-02-02 @ 4:43 AM
Study NCT ID:
NCT05579366
Status:
RECRUITING
Last Update Posted:
2025-12-05
First Post:
2022-10-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor:
Genmab
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | High Grade Epithelial Ovarian Cancer | View |
| None | High Grade Serous Ovarian Cancer | View |
| None | Primary Peritoneal Carcinoma | View |
| None | Fallopian Tube Cancer | View |
| None | Endometrial Cancer | View |
| None | Non-small Cell Lung Cancer | View |
| None | Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC) | View |
| None | Mesothelioma | View |
| None | Breast Adenocarcinoma | View |
| None | Triple Negative Breast Cancer | View |
| None | Hormone Receptor-positive/Her2 Negative Breast Cancer | View |
| None | Platinum-resistant Ovarian Cancer (PROC) | View |
| None | Platinum Sensitive Ovarian Cancer (PSOC) | View |
| None | Primary Refractory Ovarian Cancer | View |
| None | Uterine Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | antibody-drug conjugate | View |
| None | folate receptor alpha | View |
| None | folate receptor | View |
| None | solid tumor | View |
| None | ovarian cancer | View |
| None | primary peritoneal carcinoma | View |
| None | fallopian tube cancer | View |
| None | endometrial cancer | View |
| None | non-small cell lung cancer | View |
| None | mesothelioma | View |
| None | breast cancer | View |
| None | triple negative breast cancer | View |
| None | hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) … | View |
| None | topoisomerase I inhibitor | View |
| None | PROC | View |
| None | epidermal growth factor receptor (EGFR)-mutated NSCLC | View |